The landscape of biotechnology investment is undergoing a significant transformation, driven by a convergence of artificial intelligence, a shift in federal funding priorities, and a new generation of venture capital models. At the forefront of this shift is Reed Jobs, the founder of Yosemite, an oncology-focused venture firm that has rapidly ascended to become a critical player in the life sciences sector. Since its formal launch in 2023, Yosemite has distinguished itself not merely through its capital but through a unique hybrid model that blends traditional venture investment with no-strings-attached philanthropy. As the firm targets a $350 million second fund, its strategy offers a blueprint for how early-stage academic research can be bridged into clinical realities during an era of unprecedented scientific acceleration.
The Genesis and Strategic Framework of Yosemite
Yosemite was established as an independent entity after Jobs spent years leading health-related investments at Emerson Collective, the organization founded by his mother, Laurene Powell Jobs. The firm’s name is a nod to the national park where his parents were married, but its mission is strictly clinical: to accelerate the discovery and development of cancer treatments. The firm currently manages a team of 17 professionals and has built a portfolio of approximately 25 companies across two funds.
The "Yosemite Model" is predicated on the belief that the most groundbreaking cures for cancer are not currently residing within the research and development pipelines of major pharmaceutical companies. Instead, Jobs argues that these innovations are often "gentle ideas" trapped within academic laboratories at institutions like Stanford, Yale, and UC Berkeley. To extract these ideas, Yosemite utilizes a donor-advised fund (DAF) to provide philanthropic grants to researchers. These grants are unique because they carry no equity requirements or intellectual property claims, allowing scientists to de-risk their theories before they are ready for commercialization. Once a concept shows promise, Yosemite transition from philanthropist to investor, providing the venture capital necessary to spin the research out into a standalone biotech company.
According to Jobs, approximately one-third of the firm’s capital is dedicated to these self-generated startups, while the remaining two-thirds are invested in existing companies founded by external parties. This dual-track approach allows the firm to maintain a diverse exposure to the oncology market, which Jobs estimates accounts for roughly 40% of all biotechnology activity.
A Chronology of the Biotech Recovery
To understand Yosemite’s current momentum, one must look at the broader economic context of the last three years. When Jobs first began conceptualizing the firm, the biotechnology sector was reeling from a post-pandemic market correction. The SPDR S&P Biotech ETF (XBI), a common benchmark for the industry, had plummeted from its 2021 highs as interest rates rose and investors fled high-risk, pre-revenue assets.
However, by late 2023 and early 2024, the "biotech winter" began to thaw. Several factors contributed to this recovery. First, the stabilization of interest rates provided a more predictable environment for long-term capital allocation. Second, "Big Pharma" began facing a massive "patent cliff." Between 2024 and 2030, several blockbuster drugs—including oncology staples like Merck’s Keytruda and Bristol Myers Squibb’s Opdivo—are set to lose patent protection. This looming loss of revenue has forced major pharmaceutical companies to deploy record cash reserves toward acquisitions to replenish their pipelines.
This shift in the M&A environment has been palpable. In early 2024, Eli Lilly’s $7 billion acquisition of Kelonia and the massive success of antibody-drug conjugates (ADCs) signaled that the appetite for high-science oncology assets had returned. Yosemite has positioned itself to capitalize on this trend by focusing on "first-in-class" therapies that address previously undruggable targets.
The Role of Artificial Intelligence in Oncology
Perhaps the most significant enrichment to Yosemite’s strategy has been the integration of artificial intelligence. Jobs notes that AI has transitioned from a speculative curiosity to a fundamental component of drug discovery and clinical trial design. In the laboratory, AI is being used to model protein-protein interactions, a task that was historically considered too complex for traditional chemistry.
For decades, the "undruggable" targets of cancer—proteins like KRAS and p53—were viewed as smooth, featureless molecules that offered no "pockets" for drug molecules to latch onto. AI-driven structural biology has allowed researchers to identify "cryptic pockets" that open only momentarily. By utilizing machine learning to predict these movements, companies like Revolution Medicines (a high-profile player in the space) have successfully developed inhibitors for KRAS mutations in pancreatic cancer, effectively doubling survival rates in some clinical cohorts.
Beyond discovery, AI is poised to revolutionize the economics of clinical trials. A standard Phase 3 cancer trial can cost upwards of $260 million, with the primary expenses tied to patient recruitment and the maintenance of a control group. Jobs highlights the potential of "synthetic control arms," where AI uses historical patient data to create a computer-generated comparison group. This approach could potentially halve the number of human participants required for a trial, significantly reducing costs and accelerating the timeline for FDA approval.
Scientific Innovation: Epigenetics and Induced Proximity
Yosemite’s portfolio reflects a focus on cutting-edge modalities that move beyond traditional chemotherapy. One of the firm’s key pillars is epigenetic gene editing. Unlike CRISPR, which physically cuts and alters DNA sequences, epigenetic editing—led by companies like Tune Therapeutics—seeks to turn genes "on" or "off" by adding or removing methyl groups. This acts as a biological dimmer switch, allowing scientists to silence disease-driving genes without the risks associated with permanent genomic alteration.
Another area of interest is "induced proximity." Traditional drugs work by blocking a protein’s function. Induced proximity, utilized by Yosemite-backed Quarry Therapeutics, involves a drug molecule that physically drags a disease-causing protein toward the cell’s natural "trash disposal" system (the proteasome), leading to the protein’s destruction. This method is particularly effective for removing proteins that have already been synthesized and are circulating within the cell.
The firm is also tackling p53, often referred to as the "guardian of the genome." p53 is a tumor suppressor gene that is mutated or suppressed in nearly every form of human cancer. While it has long been the "holy grail" of oncology, it has remained elusive. Yosemite is currently backing three separate companies employing different strategies to either reactivate p53 or target its mutated forms, a move that Jobs believes could strike at the very "Achilles’ heel" of cancer.
Federal Funding and the NIH Debate
While private venture capital is essential, Jobs emphasizes that it cannot replace the foundational role of the National Institutes of Health (NIH). The firm has been vocal regarding federal budget proposals that suggest cuts to the NIH. In 2023, the administration proposed cuts that were historically unprecedented; for context, a 1% cut in 2009 resulted in the loss of 7,000 scientific jobs.
Jobs argues that NIH funding is one of the few areas of government spending with overwhelming bipartisan support, often exceeding 90% approval. While recent proposals for 12% to 40% cuts have been largely rejected by Congress, the Yosemite founder advocates for a more aggressive "offensive" strategy. He suggests increasing the NIH budget to $100 billion, noting that when adjusted for inflation, the agency’s purchasing power has effectively shrunk over the last decade. Without robust public funding for basic science, the pipeline of "gentle ideas" that Yosemite relies on could eventually dry up.
The Rise of the Trillion-Dollar Pharma and Longevity
The broader healthcare market has also been reshaped by the rise of GLP-1 agonists (weight-loss drugs). Eli Lilly’s ascent to a trillion-dollar valuation is a testament to the massive impact of these metabolic treatments. Jobs points out a critical intersection between GLP-1s and oncology: obesity is one of the two primary "pan-disease" risk factors, alongside smoking. By addressing obesity at scale, the medical community may see a downstream reduction in cancer incidence, potentially revitalizing interest in preventive medicine.
However, Jobs remains skeptical of the "longevity" industry as a standalone business sector. While recognizing the personal and social importance of extending human lifespan, he argues that the field lacks a "grand unified theory." Aging manifests differently across various cell types—ranging from telomere shortening to T-cell exhaustion—making a "one-size-fits-all" longevity pill unlikely. Instead, he views longevity as the byproduct of successfully managing specific diseases, such as cancer and neurodegeneration, through personalized medicine.
Impact and Implications for the Future
As Yosemite continues to deploy its second fund, the implications for the biotech ecosystem are profound. The firm’s success suggests that a hybrid model—utilizing philanthropy to bridge the "valley of death" between academia and industry—is not only viable but perhaps necessary for high-risk oncology research.
The integration of AI into this model further compresses the time-to-market for life-saving therapies. If Yosemite can continue to identify and drug previously "undruggable" targets like p53, the firm may help transition cancer from a terminal diagnosis to a manageable chronic condition. For founders and researchers, Jobs’ "open door" policy and focus on merit over pedigree signal a democratization of biotech funding, where the strength of the scientific idea takes precedence over the fame of the institution or the storyteller.
In an industry often criticized for its conservatism, Yosemite’s willingness to take "science risk" over "execution risk" represents a pivotal shift. As the firm matures, its ability to navigate the complex interplay of federal policy, AI advancement, and clinical trial innovation will likely determine its status as a leader in the next generation of life science investment.
